Repligen Corporation (RGEN)
Debt-to-capital ratio
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Long-term debt | US$ in thousands | — | — | — | — | — |
Total stockholders’ equity | US$ in thousands | 1,972,720 | 1,971,200 | 397,272 | 1,750,070 | 65,769 |
Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $1,972,720K)
= 0.00
The debt-to-capital ratio for Repligen Corporation has consistently remained at 0.00 from December 31, 2020, to December 31, 2024. This indicates that the company has not used any debt financing as part of its capital structure during this period. A debt-to-capital ratio of 0.00 signifies that the company's capital structure is predominantly equity-funded, which can be viewed positively as it implies lower financial risk and reliance on debt for operations and growth.
Peer comparison
Dec 31, 2024
Company name
Symbol
Debt-to-capital ratio
Repligen Corporation
RGEN
0.00
ADMA Biologics Inc
ADMA
0.17
Amgen Inc
AMGN
0.00
Bio-Techne Corp
TECH
0.00
Biogen Inc
BIIB
0.21
Gilead Sciences Inc
GILD
0.00
Halozyme Therapeutics Inc
HALO
0.00
Krystal Biotech Inc
KRYS
0.00
Moderna Inc
MRNA
0.00
Neurocrine Biosciences Inc
NBIX
0.00
Vericel Corp Ord
VCEL
0.00